VERU

+ Watchlist + Portfolio

Veru Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.64
52-Week Range: $2.05 – $7.33
Market Cap: $43.99M
P/E (TTM): —
EPS (TTM): -0.61
Dividend Yield: —

Advanced Metrics

Price/Book: 2.10
PEG Ratio: 3.60
Return on Equity: -64.54%
Return on Assets: -54.03%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.42
Debt/Equity: 0.09
Total Debt: $2.68M
Free Cash Flow: $-14.44M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $21.96M

VERU Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$39.35M	$16.30M	$0.00	$0.00
Cost of Revenue	$8.76M	$8.73M	$11.03M	—
Gross Profit	$30.59M	$7.57M	$5.85M	—
Research & Development	$70.91M	$51.20M	$12.78M	$15.59M
Selling, General & Admin	$43.18M	$48.06M	$24.61M	$19.94M
Operating Expenses	$114.08M	$103.17M	$37.39M	$35.53M
Operating Income	-$83.49M	-$95.61M	-$37.39M	-$35.53M
EBITDA	-$79.23M	-$89.98M	-$37.12M	-$35.38M
Pretax Income	-$83.80M	-$92.67M	-$35.26M	-$15.68M
Income Tax	$236.40K	$480.21K	$725.10K	—
Net Income	-$84.04M	-$93.15M	-$37.80M	-$22.73M
Diluted EPS	-10.50	-11.00	-2.80	-1.55
Diluted Shares	8.01M	8.50M	13.49M	14.65M

VERU Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$80.19M	$9.63M	$24.92M	$15.79M
Receivables	$3.55M	$4.51M	$3.96M	—
Inventory	$8.62M	$6.70M	$4.14M	—
Current Assets	$104.00M	$22.93M	$35.22M	$18.92M
Total Assets	$135.36M	$50.02M	$60.42M	$29.84M
Current Liabilities	$38.71M	$17.81M	$11.87M	$7.79M
Long-Term Debt	$9.66M	$8.87M	$8.85M	—
Total Debt	$15.88M	$14.41M	$13.52M	$3.12M
Total Liabilities	$52.56M	$30.34M	$28.10M	$11.50M
Retained Earnings	-$163.62M	-$256.77M	-$294.57M	-$317.30M
Shareholders' Equity	$82.80M	$19.68M	$32.32M	$18.33M
Working Capital	$65.29M	$5.12M	$23.36M	$11.13M
Net Debt	—	$109.27K	—	—

VERU Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$47.51M	-$88.01M	-$21.68M	-$30.04M
Capital Expenditure	-$733.05K	-$665.70K	-$158.32K	-$1.08K
Free Cash Flow	-$48.24M	-$88.68M	-$21.84M	-$30.04M
Depreciation & Amortisation	$209.59K	$269.87K	$268.18K	$152.10K
Stock-Based Compensation	$11.24M	$17.92M	$13.64M	$8.10M
Investing Cash Flow	$4.27M	$6.33M	$146.21K	$25.14M
Financing Cash Flow	$1.07M	$11.11M	$36.83M	-$4.22M
Net Change in Cash	-$42.17M	-$70.57M	$15.29M	-$9.12M

VERU Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.93M	$3.02M	$2.92M	$1.34M	$3.15M
Selling, General & Admin	$5.16M	$5.01M	$4.54M	$4.08M	$4.07M
Operating Expenses	$9.10M	$8.03M	$7.46M	$5.42M	$7.22M
Operating Income	-$9.10M	-$8.03M	-$7.46M	-$5.42M	-$7.22M
EBITDA	-$9.07M	-$8.00M	-$7.43M	-$5.40M	-$7.19M
Pretax Income	-$7.85M	-$7.32M	$1.30M	-$5.33M	-$3.09M
Net Income	-$7.90M	-$7.33M	$1.45M	-$5.33M	-$2.74M
Diluted EPS	-0.50	-0.50	—	-0.26	-0.12
Diluted Shares	14.64M	14.66M	—	20.31M	23.05M

VERU Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$20.02M	$15.01M	$15.79M	$32.99M	$27.60M
Current Assets	$21.38M	$16.19M	$18.92M	$36.81M	$33.36M
Total Assets	$32.67M	$27.33M	$29.84M	$47.57M	$43.08M
Current Liabilities	$5.62M	$6.68M	$7.79M	$7.13M	$5.39M
Total Debt	$3.39M	$3.25M	$3.12M	$2.98M	$2.83M
Total Liabilities	$11.62M	$11.99M	$11.50M	$10.44M	$8.30M
Retained Earnings	-$311.42M	-$318.75M	-$317.30M	-$322.63M	-$325.37M
Shareholders' Equity	$21.05M	$15.34M	$18.33M	$37.12M	$34.79M
Working Capital	$15.76M	$9.51M	$11.13M	$29.68M	$27.97M

VERU Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.74M	-$5.48M	-$5.49M	-$6.17M	-$8.91M
Free Cash Flow	-$7.74M	-$5.48M	-$5.49M	-$6.17M	-$8.91M
Depreciation & Amortisation	$29.33K	$29.33K	$28.57K	$28.19K	$28.19K
Stock-Based Compensation	$2.22M	$1.67M	$1.53M	$757.61K	$402.71K
Investing Cash Flow	$1.15M	$474.06K	$6.28M	$0.00	$3.52M
Financing Cash Flow	$0.00	$0.00	$0.00	$23.37M	$0.00
Net Change in Cash	-$6.59M	-$5.01M	$784.41K	$17.20M	-$5.39M

Market Snapshot

About

Veru Inc. is a biopharmaceutical company focused on developing medicines for breast and prostate cancers and acute respiratory distress syndrome. The company is advancing enobosarm for metastatic breast cancer and sabizabulin for severe COVID-19 and prostate cancer. Veru also markets consumer health products through its commercial division.